查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2098944

BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑市場－2026-2032年全球市場預測

Beta Lactam & Beta Lactamase Inhibitors Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，BETA-內醯胺類和BETA-內醯胺酶抑制劑市場將成長至 425.8 億美元，複合年成長率為 4.64%。

主要市場統計數據
基準年 2025 309.8億美元
預計年份：2026年 323.5億美元
預測年份 2032 425.8億美元
複合年成長率 (%) 4.64%

BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑：執行摘要

BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑在抗菌治療中仍佔核心地位。這是因為BETA-內醯胺類抗生素，例如青黴素、頭孢菌素、碳青黴烯類和單環胺基類抗生素，靶向細菌細胞壁合成，且具有長期確立的臨床安全性。然而，由於抗生素抗藥性的蔓延，特別是頻譜BETA-內醯胺酶、AmpC酶和碳青黴烯酶的出現，降低了傳統藥物的療效，它們的重要性正在重新定義。為此，BETA-內醯胺酶抑制劑的使用正在增加，以恢復或增強對院內感染、複雜性尿道感染、腹腔內感染疾病、血流感染疾病和肺炎中抗藥性革蘭氏陰性菌的抗菌活性。這一領域與合理使用抗生素、針對重點病原體的監管獎勵、診斷技術的創新以及感染預防策略密切相關。在面臨多重抗藥性感染疾病日益增多、重症監護使用範圍擴大以及監測要求日益嚴格的醫療系統中，臨床需求最為迫切。隨著抗藥性機制的演變，決策者正標靶治療、快速藥敏試驗、可靠的供應鏈以及合理使用抗生素，以在維持療效的同時改善患者預後。

治療環境的變革性變化

在BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑領域，抗菌藥物的使用正經歷著從廣泛經驗性用藥到精準指導的抗菌治療的結構性轉變。醫院正日益整合抗菌藥物使用方案、快速微生物檢測和區域抗藥性數據，以指導抑制劑組合的選擇並減少不必要的藥物暴露。難治性抗藥性革蘭氏陰性菌的出現，加速了人們對新型聯合治療的關注，這些療法旨在針對特定酶類，例如絲胺酸BETA-內醯胺酶和某些碳青黴烯酶產生菌株。監管機構和公共衛生機構持續將抗菌藥物抗藥性視為重大健康威脅，鼓勵實證用藥、感染監測以及針對重點病原體開發有效藥物。隨著醫療系統在應對短缺和品質要求的同時，努力確保基本抗生素的可靠供應，籌資策略也在改變。同時，臨床指引越來越強調降階治療、劑量最佳化、根據腎功能調整劑量、在適當情況下進行持續或序貫輸注以及藥物動力學和動態原理，從而加強了在急性護理環境中更規範地使用BETA-內醯胺酶抑制劑的模式。

人工智慧的累積影響

人工智慧正開始對BETA-內醯胺類和BETA-內醯胺酶抑制劑領域產生影響，涵蓋藥物發現、診斷、臨床決策支援和供應鏈韌性等多個面向。在藥物發現領域，機器學習模型被用於篩檢化合物庫、預測與BETA-內醯胺酶的結合行為、確定分子修飾的優先級，並識別對抗藥性病原體具有更高活性的候選化合物。在臨床微生物學領域，人工智慧驅動的藥敏模式和基因組抗藥性標記的解讀，經過檢查室標準檢驗後，有助於更快選擇治療方案。在醫院，預測分析可以識別多重抗藥性感染疾病風險患者、最佳化經驗性治療方案，並加強抗菌藥物監測（ASM）措施。人工智慧還可以透過從真實世界數據中檢測安全訊號來改善藥物安全監測，並透過預測關鍵注射用抗生素的需求波動來加強供應鏈規劃。然而，為了避免不恰當的處方、偏見或過度依賴演算法輸出，實施必須以證據為基礎，由臨床管理，並符合資料隱私、模型透明度、抗生素使用和檢查室檢驗要求。

按地區分類的主要發現

亞太地區對BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑至關重要，因為該感染疾病負擔沉重，都市區密度高，抗生素消耗量巨大，且多個醫療系統都面臨抗生素抗藥性方面的挑戰。儘管中國、印度、日本、韓國、澳洲和東南亞國協正在加強監測、藥物管理和國內製藥能力，但醫院的需求仍與抗藥性革蘭氏陰性病菌感染、重症監護的擴展以及檢測能力的提高密切相關。北美地區的特點是醫院合理用藥計畫完善、法律規範嚴格、藥敏試驗廣泛應用，公共衛生部門持續關注耐碳青黴烯類腸桿菌、頻譜BETA-內醯胺酶產生菌和其他多重抗藥性病原體。在歐洲，協調一致的抗生素抗藥性監測、基於指南的處方、藥物安全監測以及對感染預防的高度重視已被證明是有效的，儘管北部、西部、南部和東部各國之間的抗藥性模式存在顯著差異。在拉丁美洲，都市區三級醫療機構能夠應對複雜的抗藥性感染疾病，但公立和私立醫療體系的情況各不相同，在醫療服務可近性、診斷能力和藥物使用管理方面存在差異。在中東，對醫院基礎設施、抗生素使用和感染控制的投資正在增加，而在海灣合作理事會（GCC）國家，醫療現代化、監測和基於規範的醫院感染控制則更為重要。非洲面臨感染疾病負擔沉重和診斷資源匱乏的雙重挑戰，因此，合理使用BETA-內醯胺類抗生素、品質保證、抗生素使用和抗藥性監測對於患者照護和公共衛生至關重要。

關鍵區域洞察

隨著各國政府擴大全民健康覆蓋（UHC）、提升醫院容量並加強抗菌藥物抗藥性防治項目，同時應對高抗生素使用率和檢測系統差異等問題，東南亞國協在BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑領域的重要性日益凸顯。海灣合作理事會（GCC）國家正積極推動醫療現代化、建立專科醫院網路、完善感染控制項目和抗菌藥物管理框架，從而支持更多地採用基於規範的治療方案來對抗抗藥性醫院獲得性病原體。歐盟為抗菌藥物抗藥性監測、藥物安全監測、品質標準和跨境公共衛生合作提供了最為完善的環境之一，並對以指南為基礎的處方、循證醫學和藥物保護為重點的抗菌藥物政策具有重大影響。金磚國家擁有龐大的患者群體、強大的藥品生產能力和不斷成長的醫院需求，但也面臨著抗藥性模式的多樣性和抗菌藥物管理成熟度的差異，因此迫切需要基於診斷的抗菌藥物選擇和品質保證的供應。七國集團透過先進的監管科學、公共衛生監測、研究經費、合理用藥計劃以及針對重點抗藥性病原體和醫院感染的政策，發揮著重要的影響力。北約成員國，其中許多與醫療衛生已開發經濟體重疊，更加重視發展醫療衛生體系、保障供應鏈安全以及提升應對感染疾病威脅的能力，這進一步凸顯了可靠獲取BETA-內醯胺類抗生素和BETA-內醯胺酶抑製劑的戰略重要性。

主要國家的概況

美國仍然是BETA-內醯胺類抗生素和BETA-內頻譜抑製劑的主要使用中心，這主要得益於其先進的醫院醫療保健體系、對抗生素廣泛使用的預期以及對包括碳青黴烯耐藥菌和廣譜BETA-內醯胺酶產生菌在內的緊急耐藥威脅的監測。加拿大強調公共衛生監測、抗生素使用以及各省醫療保健系統內抗生素的公平獲取，而墨西哥除了面臨都市區醫院日益成長的需求外，還面臨著抗藥性監測和合理使用抗生素方面的挑戰。巴西由於革蘭氏陰性病菌感染的增加以及其大規模的公共和私人醫療保健網路，醫院對抗生素的需求量龐大。在歐洲，英國、德國、法國、義大利和西班牙依賴基於指南的處方、微生物檢測能力和抗生素使用方案，儘管與北歐國家相比，南歐國家歷來報告某些革蘭氏陰性病原體的抗藥性壓力更高。俄羅斯面臨著複雜的環境，受到醫院感染負擔、抗生素抗藥性區域差異以及不斷變化的合理使用抗生素優先事項的影響。中國和印度由於其龐大的人口、高抗生素消耗量、國內生產能力以及加強的國家抗抗抗生素抗藥性行動計劃，佔據著至關重要的地位。日本和韓國擁有先進的診斷技術、老齡化人口以及健全的醫院系統，這些都支持在臨床適用的情況下系統性地使用新的聯合治療。澳洲擁有完善的抗生素使用管理和監測系統，其處方實踐受到國家指南、區域抗藥性模式和感染控制標準的指導。

為行業領導者提供的實用建議

產業領導者應優先考慮以實證醫學為基礎、針對具有臨床意義的抗藥性機制的產品組合策略，而非盲目擴大抗生素的使用範圍。對BETA-內醯胺酶抑制劑創新的投資應與檢驗的伴隨診斷、快速藥敏試驗合作以及藥物動力學和動態最佳化相結合，以支持精準的臨床應用。生產者和醫療保健相關人員應加強品質保證生產、實現採購多元化，並採取措施緩解必需的BETA-內醯胺類注射和口服製劑的供不應求。參與合理使用抗生素計畫至關重要，包括進行合理適應症、分階段治療、根據腎功能調整劑量、靜脈給藥策略、盡可能進行治療監測以及抗藥性監測的教育。各機構應收集關於臨床結果、安全性、抗藥性出現以及在醫療保健系統中價值的真實世界數據（REW），同時避免不必要的處方。獲取策略必須體現新型抗生素的公共衛生價值，並透過管理式使用模式支持資源節約。此外，領導者需要與醫院、實驗室、監管機構和公共衛生機構合作，以改善抗藥性負擔重、診斷能力有限的地區的監測數據、管理合規性和獲得有效治療的機會。

調查方法

本執行摘要基於二手研究、臨床和監管資料審查以及對已發表的關於BETA-內醯胺類抗生素、BETA-內醯胺酶抑製劑、抗菌藥物耐藥性、合理用藥實踐、區域醫療保健趨勢和感染疾病控制的證據進行系統解讀而撰寫。檢驗調查方法強調來自同行評審文獻、公共衛生機構和監管公告、抗菌藥物抗藥性監測系統、臨床指南、基本藥物指南和醫院合理用藥框架的已驗證數據。透過評估抗藥性機制、治療應用、診斷方法、政策趨勢、供應考慮和區域醫療保健基礎設施，整合了相關見解。本分析不包括市場規模、市場佔有率、公司定位和預測。區域、群體和國家觀點的評估是基於已記錄的醫療保健服務能力、抗藥性監測、合理用藥成熟度、抗生素可近性和政策方向。透過交叉引用多個可靠資訊來源，並使術語與感染疾病、微生物學和藥理學領域的既定標準保持一致，檢驗了研究結果，從而確保其準確性、相關性和一致性，以滿足特定行業受眾的需求。

結論

儘管BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑療法在現代感染疾病控制中仍至關重要，但其長期價值取決於合理用藥、避免處方抗藥性細菌、確保診斷準確性以及提供可靠的藥物。在應對多重抗藥性革蘭氏陰性菌的同時，透過藥物管理和感染預防來維持抗生素的有效性，這一領域的發展日益受到挑戰。人工智慧、快速診斷和真實世界數據，若在嚴格的檢驗和管治下實施，將有助於改善新藥研發、臨床決策、藥物安全監測和供應規劃。抗生素抗藥性負擔、醫療基礎設施、診斷可近性和藥物管理成熟度的區域差異將繼續影響藥物部署和治療重點。能夠將創新與公共衛生需求、高品質生產、協調監測和臨床嚴格的藥物獲取模式相結合的行業領導者，將最有利於支持永續的抗菌治療。最有效的策略是在治療進展與資源節約之間取得平衡，確保BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑的聯合治療仍然是治療嚴重細菌感染疾病的可靠選擇。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑市場：依藥物類別分類

  • 碳青黴烯類
    • 多利培南
    • 艾爾他培南
    • Imipenem
    • Meropenem
  • 頭孢菌素
    • 第五代頭孢菌素
    • 第一代頭孢菌素
    • 第四代頭孢菌素
    • 第二代頭孢菌素
    • 第三代頭孢菌素
  • 單環胺基類
  • 青黴素
    • 氨基青黴素
    • 頻譜青黴素
    • 天然青黴素

第8章：BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑市場：依給藥途徑分類

  • 口服
    • 膠囊
    • 藥片
  • 腸外給藥
    • 肌肉內部
    • 靜脈

第9章：BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑市場：依患者類型分類

  • 成年患者
    • 中年人和老年人
    • 老年人
    • 青年人
  • 兒童患者
    • 青春期
    • 孩子們
    • 嬰兒
    • 新生

第10章：BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑市場：依應用領域分類

  • 婦科感染疾病
  • 腹腔內感染疾病
  • 術中預防
  • 呼吸道感染疾病
  • 皮膚感染疾病
    • 蜂窩組織炎
    • 丹毒
    • 膿皰瘡
  • 尿道感染
    • 急性尿道感染
    • 慢性尿道感染

第11章 BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑市場：依最終用戶分類

  • 學術機構
  • 診所
  • 醫院
  • 研究所

第12章 BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 BETA-內醯胺類抗生素和BETA-內醯胺酶抑制劑市場：依國家分類

  • 美國
  • 德國
  • 中國
  • 英國
  • 印度
  • 日本
  • 法國
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 俄羅斯
  • 西班牙
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Centrient Pharmaceuticals Netherlands BV
  • Cipla Ltd.
  • Creative Diagnostics
  • F. Hoffmann-La Roche AG
  • Marubeni Corporation
  • Melinta Therapeutics, LLC
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Protech Telelinks
  • Qpex Biopharma, Inc. by Shionogi Inc.
  • SciClone Pharmaceuticals（Holdings）Limited
  • Sumitomo Pharma Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • TOKU-E
  • Venatorx Pharmaceuticals, Inc.
  • Zai Lab Limited
Product Code: MRR-450A0628C441

The Beta Lactam & Beta Lactamase Inhibitors Market is projected to grow by USD 42.58 billion at a CAGR of 4.64% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 30.98 billion
Estimated Year [2026] USD 32.35 billion
Forecast Year [2032] USD 42.58 billion
CAGR (%) 4.64%

Beta Lactam & Beta Lactamase Inhibitors Executive Summary

Beta lactam and beta lactamase inhibitor therapies remain central to antibacterial treatment because beta lactam antibiotics, including penicillins, cephalosporins, carbapenems, and monobactams, target bacterial cell wall synthesis with a long-established clinical safety profile. Their continued relevance is being reshaped by antimicrobial resistance, particularly the spread of extended-spectrum beta lactamases, AmpC enzymes, and carbapenemases that reduce the effectiveness of traditional agents. In response, beta lactamase inhibitors are increasingly used to restore or extend antibacterial activity against resistant Gram-negative pathogens in hospital-acquired infections, complicated urinary tract infections, intra-abdominal infections, bloodstream infections, and pneumonia. The sector is closely linked to antimicrobial stewardship, regulatory incentives for priority pathogens, diagnostic innovation, and infection prevention strategies. Clinical demand is strongest where healthcare systems face rising multidrug-resistant infections, expanding intensive care utilization, and heightened surveillance requirements. As resistance mechanisms evolve, decision-makers are prioritizing targeted therapy, rapid susceptibility testing, reliable supply chains, and responsible antibiotic use to preserve efficacy while improving patient outcomes.

Transformative Shifts in the Treatment Landscape

The beta lactam and beta lactamase inhibitors landscape is undergoing a structural shift from broad empiric prescribing toward precision-guided antibacterial therapy. Hospitals are increasingly integrating antimicrobial stewardship programs, rapid microbiology, and local resistance data to guide selection of inhibitor combinations and reduce unnecessary exposure. The emergence of difficult-to-treat resistant Gram-negative organisms has accelerated interest in novel combinations designed to address specific enzyme classes, including serine beta lactamases and selected carbapenemase-producing strains. Regulatory agencies and public health bodies continue to classify antimicrobial resistance as a critical health threat, encouraging evidence-based use, infection surveillance, and development of agents active against priority pathogens. Procurement strategies are also changing as health systems seek dependable access to essential antibiotics while managing shortages and quality requirements. At the same time, clinical guidelines increasingly emphasize de-escalation, dose optimization, renal adjustment, extended or continuous infusion where appropriate, and pharmacokinetic-pharmacodynamic principles, reinforcing a more disciplined model for beta lactamase inhibitor deployment across acute care settings.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the beta lactam and beta lactamase inhibitors field across discovery, diagnostics, clinical decision support, and supply resilience. In drug discovery, machine learning models are being used to screen chemical libraries, predict beta lactamase binding behavior, prioritize molecular modifications, and identify candidates with improved activity against resistant pathogens. In clinical microbiology, AI-assisted interpretation of susceptibility patterns and genomic resistance markers can support faster therapy selection when validated against laboratory standards. In hospitals, predictive analytics can help identify patients at risk for multidrug-resistant infections, optimize empiric therapy pathways, and strengthen antimicrobial stewardship interventions. AI can also improve pharmacovigilance by detecting safety signals from real-world data and enhance supply chain planning by anticipating demand volatility for critical injectable antibiotics. However, implementation must be evidence-led, clinically governed, and aligned with data privacy, model transparency, antimicrobial stewardship, and laboratory validation requirements to avoid inappropriate prescribing, bias, or overreliance on algorithmic outputs.

Key Regional Insights

Asia-Pacific is a critical region for beta lactam and beta lactamase inhibitors due to high infectious disease burden, dense urban populations, substantial antibiotic consumption, and documented challenges with antimicrobial resistance across several healthcare systems. China, India, Japan, South Korea, Australia, and ASEAN economies are strengthening surveillance, stewardship, and domestic pharmaceutical capabilities, while hospital demand remains closely tied to resistant Gram-negative infections, critical care expansion, and improved laboratory capacity. North America is characterized by advanced hospital stewardship programs, strong regulatory oversight, broad use of susceptibility testing, and sustained public health attention to carbapenem-resistant Enterobacterales, extended-spectrum beta lactamase-producing organisms, and other multidrug-resistant pathogens. Europe benefits from coordinated antimicrobial resistance surveillance, guideline-driven prescribing, pharmacovigilance, and strong emphasis on infection prevention, although resistance patterns vary significantly between northern, western, southern, and eastern countries. Latin America faces a mixed landscape where urban tertiary hospitals manage complex resistant infections while access, diagnostics, and stewardship capacity remain uneven across public and private systems. The Middle East is increasing investment in hospital infrastructure, antimicrobial stewardship, and infection control, with GCC countries emphasizing healthcare modernization, surveillance, and protocol-based management of hospital-acquired infections. Africa faces the dual challenge of high infectious disease burden and constrained diagnostic access, making appropriate beta lactam use, quality-assured supply, antimicrobial stewardship, and resistance monitoring essential for patient care and public health.

Key Group Insights

ASEAN countries are increasingly important in the beta lactam and beta lactamase inhibitors landscape as governments expand universal health coverage, hospital capacity, and antimicrobial resistance action plans while managing high antibiotic utilization and variable laboratory infrastructure. The GCC is advancing healthcare modernization, specialist hospital networks, infection control programs, and antimicrobial stewardship frameworks, supporting greater use of protocol-driven therapy for resistant hospital pathogens. The European Union provides one of the most structured environments for antimicrobial resistance surveillance, pharmacovigilance, quality standards, and cross-border public health coordination, making it influential in guideline-based prescribing, evidence generation, and conservation-focused antibiotic policy. BRICS economies combine large patient populations, substantial pharmaceutical manufacturing capabilities, and rising hospital demand, but they also face diverse resistance patterns and uneven stewardship maturity, creating strong need for diagnostics-led antibiotic selection and quality-assured supply. G7 countries are influential through advanced regulatory science, public health surveillance, research funding, stewardship initiatives, and policy attention to priority resistant pathogens and hospital-acquired infections. NATO member states, many of which overlap with advanced healthcare economies, place additional emphasis on medical readiness, secure supply chains, and response capacity for infectious disease threats, reinforcing the strategic importance of reliable beta lactam and beta lactamase inhibitor access.

Key Country Insights

The United States remains a major center for beta lactam and beta lactamase inhibitor utilization due to advanced hospital care, robust stewardship expectations, and surveillance of urgent resistant threats, including carbapenem-resistant and extended-spectrum beta lactamase-producing organisms. Canada emphasizes public health surveillance, stewardship, and equitable access across provincial healthcare systems, while Mexico faces growing demand in urban hospitals alongside challenges in resistance monitoring and appropriate antibiotic use. Brazil has significant hospital-based need driven by resistant Gram-negative infections and large public and private healthcare networks. In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on guideline-led prescribing, microbiology capacity, and stewardship programs, though southern European countries have historically reported higher resistance pressures for several Gram-negative pathogens than some northern counterparts. Russia presents a complex environment shaped by hospital infection burden, regional variation in antimicrobial resistance, and evolving stewardship priorities. China and India are pivotal due to large populations, high antibiotic consumption, domestic manufacturing capabilities, and intensified national action plans for antimicrobial resistance. Japan and South Korea combine advanced diagnostics, aging populations, and strong hospital systems, supporting structured use of newer combinations where clinically indicated. Australia has well-developed stewardship and surveillance systems, with prescribing shaped by national guidance, local resistance patterns, and infection control standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based portfolio strategies that address clinically significant resistance mechanisms rather than undifferentiated antibiotic expansion. Investment in beta lactamase inhibitor innovation should be paired with validated companion diagnostics, rapid susceptibility testing partnerships, and pharmacokinetic-pharmacodynamic optimization to support precise clinical use. Manufacturers and healthcare stakeholders should strengthen quality-assured production, diversified sourcing, and shortage mitigation plans for essential beta lactam injectables and oral formulations. Engagement with antimicrobial stewardship programs is essential, including education on appropriate indications, de-escalation, renal dose adjustment, infusion strategies, therapeutic drug monitoring where available, and resistance monitoring. Organizations should generate real-world evidence on clinical outcomes, safety, resistance emergence, and health system value without encouraging unnecessary prescribing. Access strategies should reflect the public health value of novel antibiotics while supporting conservation through controlled use models. Leaders should also collaborate with hospitals, laboratories, regulators, and public health agencies to improve surveillance data, stewardship compliance, and access to effective therapy in regions with high resistance burden and limited diagnostic capacity.

Research Methodology

This executive summary is developed through secondary research, clinical and regulatory source review, and structured interpretation of publicly available evidence on beta lactam antibiotics, beta lactamase inhibitors, antimicrobial resistance, stewardship practices, regional healthcare dynamics, and infectious disease management. The methodology emphasizes verified data from peer-reviewed literature, public health agencies, regulatory communications, antimicrobial resistance surveillance systems, clinical guidelines, essential medicines guidance, and hospital stewardship frameworks. Insights are synthesized by evaluating resistance mechanisms, therapeutic applications, diagnostic adoption, policy developments, supply considerations, and regional healthcare infrastructure. The analysis excludes market sizing, market share, company-specific positioning, and forecasting. Regional, group, and country perspectives are assessed based on documented healthcare capacity, resistance surveillance, stewardship maturity, antibiotic access, and policy direction. Findings are validated through cross-referencing multiple credible sources and aligning terminology with established infectious disease, microbiology, and pharmacology standards to ensure accuracy, relevance, and alignment for industry-specific audiences.

Conclusion

Beta lactam and beta lactamase inhibitor therapies will remain essential to modern infectious disease management, but their long-term value depends on responsible use, resistance-informed prescribing, diagnostic precision, and reliable access. The sector is increasingly shaped by the need to counter multidrug-resistant Gram-negative pathogens while preserving antibiotic effectiveness through stewardship and infection prevention. Artificial intelligence, rapid diagnostics, and real-world evidence can improve discovery, clinical decision-making, pharmacovigilance, and supply planning when implemented with strong validation and governance. Regional differences in resistance burden, healthcare infrastructure, diagnostic access, and stewardship maturity will continue to influence adoption and therapeutic priorities. Industry leaders that align innovation with public health needs, quality manufacturing, surveillance collaboration, and clinically disciplined access models will be best positioned to support sustainable antibacterial care. The most effective strategies will balance therapeutic advancement with conservation, ensuring that beta lactam and beta lactamase inhibitor combinations remain dependable tools against serious bacterial infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Carbapenems
    • 7.2.1. Doripenem
    • 7.2.2. Ertapenem
    • 7.2.3. Imipenem
    • 7.2.4. Meropenem
  • 7.3. Cephalosporins
    • 7.3.1. Fifth-Generation Cephalosporins
    • 7.3.2. First-Generation Cephalosporins
    • 7.3.3. Fourth-Generation Cephalosporins
    • 7.3.4. Second-Generation Cephalosporins
    • 7.3.5. Third-Generation Cephalosporins
  • 7.4. Monobactam
  • 7.5. Penicillins
    • 7.5.1. Aminopenicillins
    • 7.5.2. Extended-Spectrum Penicillins
    • 7.5.3. Natural Penicillins

8. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral Administration
    • 8.2.1. Capsules
    • 8.2.2. Tablets
  • 8.3. Parenteral Administration
    • 8.3.1. Intramuscular
    • 8.3.2. Intravenous

9. Beta Lactam & Beta Lactamase Inhibitors Market, by Patient Type

  • 9.1. Introduction
  • 9.2. Adult Patients
    • 9.2.1. Middle-Aged Adults
    • 9.2.2. Senior Adults
    • 9.2.3. Young Adults
  • 9.3. Pediatric Patients
    • 9.3.1. Adolescents
    • 9.3.2. Children
    • 9.3.3. Infants
    • 9.3.4. Neonates

10. Beta Lactam & Beta Lactamase Inhibitors Market, by Application

  • 10.1. Introduction
  • 10.2. Gynecological Infections
  • 10.3. Intrabdominal Infections
  • 10.4. Intraoperative Prophylaxis
  • 10.5. Respiratory Infections
  • 10.6. Skin Infections
    • 10.6.1. Cellulitis
    • 10.6.2. Erysipelas
    • 10.6.3. Impetigo
  • 10.7. Urinary Tract Infections
    • 10.7.1. Acute UTI
    • 10.7.2. Chronic UTI

11. Beta Lactam & Beta Lactamase Inhibitors Market, by End User

  • 11.1. Introduction
  • 11.2. Academic Institutions
  • 11.3. Clinics
  • 11.4. Hospitals
  • 11.5. Research Laboratories

12. Beta Lactam & Beta Lactamase Inhibitors Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Beta Lactam & Beta Lactamase Inhibitors Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Beta Lactam & Beta Lactamase Inhibitors Market, by Country

  • 14.1. United States
  • 14.2. Germany
  • 14.3. China
  • 14.4. United Kingdom
  • 14.5. India
  • 14.6. Japan
  • 14.7. France
  • 14.8. Brazil
  • 14.9. Canada
  • 14.10. Italy
  • 14.11. Mexico
  • 14.12. Russia
  • 14.13. Spain
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Aurobindo Pharma Limited
  • 16.3. Bio-Rad Laboratories, Inc.
  • 16.4. Bristol-Myers Squibb Company
  • 16.5. Centrient Pharmaceuticals Netherlands B.V.
  • 16.6. Cipla Ltd.
  • 16.7. Creative Diagnostics
  • 16.8. F. Hoffmann-La Roche AG
  • 16.9. Marubeni Corporation
  • 16.10. Melinta Therapeutics, LLC
  • 16.11. Merck KGaA
  • 16.12. Novartis AG
  • 16.13. Pfizer Inc.
  • 16.14. Protech Telelinks
  • 16.15. Qpex Biopharma, Inc. by Shionogi Inc.
  • 16.16. SciClone Pharmaceuticals (Holdings) Limited
  • 16.17. Sumitomo Pharma Co., Ltd.
  • 16.18. Thermo Fisher Scientific Inc.
  • 16.19. TOKU-E
  • 16.20. Venatorx Pharmaceuticals, Inc.
  • 16.21. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARBAPENEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARBAPENEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARBAPENEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DORIPENEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DORIPENEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DORIPENEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ERTAPENEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ERTAPENEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ERTAPENEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMIPENEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMIPENEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMIPENEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MEROPENEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEROPENEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MEROPENEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FIFTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FIFTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FIFTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FIRST-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FIRST-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FIRST-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FOURTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FOURTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FOURTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SECOND-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SECOND-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SECOND-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THIRD-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THIRD-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THIRD-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONOBACTAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONOBACTAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONOBACTAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMINOPENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AMINOPENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMINOPENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EXTENDED-SPECTRUM PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EXTENDED-SPECTRUM PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EXTENDED-SPECTRUM PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PARENTERAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PARENTERAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PARENTERAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MIDDLE-AGED ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MIDDLE-AGED ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MIDDLE-AGED ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SENIOR ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SENIOR ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SENIOR ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL YOUNG ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL YOUNG ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL YOUNG ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADOLESCENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ADOLESCENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADOLESCENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHILDREN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHILDREN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEONATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEONATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEONATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GYNECOLOGICAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GYNECOLOGICAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GYNECOLOGICAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTRABDOMINAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INTRAOPERATIVE PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRAOPERATIVE PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INTRAOPERATIVE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SKIN INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SKIN INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SKIN INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELLULITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CELLULITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELLULITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ERYSIPELAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ERYSIPELAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ERYSIPELAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMPETIGO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IMPETIGO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMPETIGO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ACUTE UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CHRONIC UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHRONIC UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CHRONIC UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 267. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 301. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 302. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 308. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 309. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 310. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 311. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 312. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 315. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 316. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 317. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 318. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
  • TABLE 323. NATO BETA LACTAM & BETA LACTAMASE INHIBITO